<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5647433</article-id><article-id pub-id-type="pmid">29044172</article-id><article-id pub-id-type="publisher-id">13875</article-id><article-id pub-id-type="doi">10.1038/s41598-017-13875-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Copier</surname><given-names>Camila Uribe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Le&#x000f3;n</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fern&#x000e1;ndez</surname><given-names>Mauricio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Contador</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Calligaris</surname><given-names>Sebasti&#x000e1;n D.</given-names></name><address><email>scalligaris@udd.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Centro de Medicina Regenerativa, Facultad de Medicina, Cl&#x000ed;nica Alemana Universidad del Desarrollo, Av. Las Condes 12.438, Lo Barnechea, Santiago Chile </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.441837.d</institution-id><institution>Instituto de Ciencias Biom&#x000e9;dicas, Facultad de Ciencias de la Salud, Universidad Aut&#x000f3;noma de Chile, Pedro de Valdivia 425, </institution></institution-wrap>Providencia, Santiago Chile </aff><aff id="Aff3"><label>3</label>Departamento de Cardiolog&#x000ed;a, Cl&#x000ed;nica Alemana de Santiago - Universidad del Desarrollo, Vitacura 5951, Vitacura, Santiago Chile </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>7</volume><elocation-id>13514</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Diabetic cardiomyopathy is characterized by metabolic changes in the myocardium that promote a slow and silent dysfunction of muscle fibers, leading to myocardium remodelling and heart failure, independently of the presence of coronary artery diseases or hypertension. At present, no imaging methods allow an early diagnosis of this disease. Circulating miRNAs in plasma have been proposed as biomarkers in the prognosis of several cardiac diseases. This study aimed to determine whether circulating miRNAs could be potential biomarkers of diabetic cardiomyopathy. Mice that were fed with a high fat diet for 16 months, showed metabolic syndrome manifestations, cardiac hypertrophy (without hypertension) and a progressive cardiac function decline. At 16 months, when maximal degree of cardiac dysfunction was observed, 15 miRNAs from a miRNA microarray screening in myocardium were selected. Then, selected miRNAs expression in myocardium (at 4 and 16 months) and plasma (at 4, 12 and 16 months) were measured by RT-qPCR. Circulating miR-19b-3p and miR-181b-5p levels were associated with myocardium levels during the development of diabetic cardiomyopathy (in terms of cardiac dysfunction), suggesting that these miRNAs could be suitable biomarkers of this disease in asymptomatic diabetic patients.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Diabetes Mellitus (DM) has shown an increasing prevalence since 1980. In 2014, it was estimated that 422 million adults lived with DM and approximately 4.9 million people died from complications related to diabetes, and positioned cardiovascular disease as the major cause of death<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>.</p><p id="Par3">Diabetic patients could have an asymptomatic cardiac function alteration without coronary arterial diseases, hypertension, or any congenital cardiac disease. This manifestation was defined as diabetic cardiomyopathy in 1972, and its implications in the integral treatment of cardiac disease related to DM in patients have aroused increasing interest in the scientific and clinical community<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>. During the latency period of the diabetic cardiomyopathy, alterations of the energetic metabolic and myocardial structure lead to a diastolic dysfunction, which progresses to concentric ventricular hypertrophy and a reduction of its contractile reserve, eventually reaching systolic dysfunction<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par4">In a population-based study performed in Olmsted County (USA), 1.1% of the community met criteria for diabetic cardiomyopathy, increasing to 16,9% in asymptomatic diabetic patients, of which 54.4% had diastolic dysfunction<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. In another study in Bruderholz (Switzerland), 58% of diabetic patients, without previous evidence of structural heart diseases, were diagnosed with diabetic cardiomyopathy<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par5">Currently, therapy for diabetic cardiomyopathy is based on strict glycemic control, changes in lifestyle favoring exercise, balanced calorie intake and administration of beta-blockers and angiotensin converting enzyme inhibitors. Several observational studies show that the effectiveness of these treatments increase significantly when diabetic cardiomyopathy is detected in its early stages<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par6">The lack of specific characteristics makes the detection of diabetic cardiomyopathy a challenge in clinical practice. The diagnosis in asymptomatic diabetic patients without hypertension and coronary diseases is based on the detection of cardiac hypertrophy and diastolic dysfunction by echocardiography<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par7">Currently no blood or imaging test is available for diagnosis prior to irreversible heart remodeling; however, circulating long-non-coding RNA or microRNAs (miRNAs) have been proposed as new type of biomarkers for cardiovascular diseases, mainly because they are involved in epigenetics mechanisms of cardiomyopathies<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref></sup>. MiRNAs are small non-coding RNA molecules that function as post&#x02013;transcriptional regulators, decreasing expression of target genes and regulating multiple cellular pathways. A key attribute that support their use is their stability in plasma, because they are within exosomes and high density lipoproteins (HDL) and can form complex soluble proteins.</p><p id="Par8">One approach to discover novel miRNAs as biomarkers, is the use of animal models to correlate their gene expression patterns in the damaged-tissue with their levels in biofluids. This strategy has the advantage of strongly associating a circulating miRNA signature with a specific organ state in a multiple DM-related complications scenario<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. In the present study, we used a diabetic cardiomyopathy mice model, induced by a high-fat diet, to correlate the miRNA relative abundance in plasma with their expression in myocardium and cardiac function decline during the development of diabetic cardiomyopathy secondary to obesity. We identified two miRNAs whose relative abundance in plasma is reduced before cardiac dysfunctions appear; thus, we propose them as potential biomarkers for diabetic cardiomyopathy.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Diabetic cardiomyopathy animal model characteristics</title><p id="Par9">Animals fed with a high-fat diet for 4 months (at the beginning of the study) were overweight (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref>), and they presented elevated plasma non-ester fatty acid (NEFA) levels (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B</xref>), hyperglycaemia (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>), and glucose intolerance (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1D</xref>) in comparison with mice fed with a standard diet. All of these features in the high-fat diet mice are characteristics of metabolic syndrome, which remained until the end of the study<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.<fig id="Fig1"><label>Figure 1</label><caption><p>Characteristics of the obesity animal model induced by high fat diet. After 4 months of high-fat diet treatment, body weight (<bold>A</bold>), plasma NEFA, glucose (<bold>B</bold> and <bold>C</bold> respectively), and a glucose tolerance test (<bold>D</bold>) were assessed. (n&#x02009;=&#x02009;6&#x02013;7) Mean&#x02009;&#x000b1;&#x02009;SEM, *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001 vs. normal mice (t-Student test and Two-way ANOVA test).</p></caption><graphic xlink:href="41598_2017_13875_Fig1_HTML" id="d29e332"/></fig>
</p><p id="Par10">With regard to cardiovascular characteristic of the animal model, mean arterial pressure slightly decreased during the whole dietary treatment in obese mice, without statistical difference between both experimental groups (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1SA</xref>). However, after 4 months of dietary treatment, the obese mice (O) presented a heart mass higher than that of normal mice (N), resulting in cardiac hypertrophy (160&#x02009;&#x000b1;&#x02009;4&#x02009;mg, O <italic>vs</italic>. 131&#x02009;&#x000b1;&#x02009;3&#x02009;mg, N; p&#x02009;&#x0003c;&#x02009;0.001), which remained until the end of the study (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1SC</xref>). Consistent with these results, the cross-sectional area of cardiomyocyte was higher in obese myocardium in comparison to normal myocardium (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1SD</xref>). Interestingly, normal mice underwent an age-related cardiac hypertrophy (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1SC</xref>). In addition, left ventricular end-diastolic pressure (LVEDP) was also higher in obese mice, which is a functional indicator of cardiac remodelling (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1SB</xref>). The obese mice had cardiac hypertrophy despite their normotensive state, which is a characteristic of diabetic cardiomyopathy.</p><p id="Par11">Regarding cardiac function at basal condition, high fat diet feeding induced systolic dysfunction (<italic>d</italic>P/<italic>d</italic>t<sub>max</sub>: 5768&#x02009;&#x000b1;&#x02009;341&#x02009;mmHg, O <italic>vs</italic>. 7255&#x02009;&#x000b1;&#x02009;330&#x02009;mmHg, N; p&#x02009;&#x0003c;&#x02009;0.05) and diastolic dysfunction (<italic>d</italic>P/<italic>d</italic>t<sub>min</sub>: &#x02212;55297&#x02009;&#x000b1;&#x02009;258&#x02009;mmHg, O <italic>vs</italic>. &#x02212;7117&#x02009;&#x000b1;&#x02009;243&#x02009;mmHg, N; p&#x02009;&#x0003c;&#x02009;0.01) in obese mice only at 16 months (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2A and B</xref> respectively). However, when obese mice were exposed to a cardiac stress test (with dobutamine), systolic and diastolic dysfunctions were observed at 12 months ((<italic>d</italic>P/<italic>d</italic>t<sub>max</sub>: 8975&#x02009;&#x000b1;&#x02009;538&#x02009;mmHg, O <italic>vs</italic>. 11925&#x02009;&#x000b1;&#x02009;281&#x02009;mmHg, N; p&#x02009;&#x0003c;&#x02009;0.05 and <italic>d</italic>P/<italic>d</italic>t<sub>min</sub>: &#x02212;8270&#x02009;&#x000b1;&#x02009;561&#x02009;mmHg, O <italic>vs</italic>. &#x02212;10744&#x02009;&#x000b1;&#x02009;387&#x02009;mmHg, N; p&#x02009;&#x0003c;&#x02009;0.05), indicating that the performance of an obese heart is altered before it manifests at basal condition (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2C</xref> y&#x000a0;<xref rid="Fig2" ref-type="fig">2D</xref> respectively). According to these results, three endpoints in the progression of cardiac dysfunction were defined in order to study search miRNAs useful for biomarker applications.<fig id="Fig2"><label>Figure 2</label><caption><p>Cardiac function under basal and stress conditions. Cardiac catheterization under basal (<bold>A</bold>,<bold>B</bold>) and stress conditions by dobutamine (<bold>C</bold>,<bold>D</bold>). In the cardiac stress test, max-peak of stimulation with dobutamine were considered to obtained <italic>d</italic>P/<italic>d</italic>t<sub>max</sub> and <italic>d</italic>P/<italic>d</italic>t<sub>min</sub>. Solid and dotted lines indicate were used to indicate normal and obese mice respectively. (n&#x02009;=&#x02009;7). Mean&#x02009;&#x000b1;&#x02009;SEM, *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001 vs. normal mice (Two-way ANOVA test).</p></caption><graphic xlink:href="41598_2017_13875_Fig2_HTML" id="d29e456"/></fig>
</p></sec><sec id="Sec4"><title>MiRNA differentially expressed in myocardium during diabetic cardiomyopathy progression</title><p id="Par12">MiRNA expression profile was comprehensively analysed in myocardium of obese mice at 16 months (maximal degree of cardiac dysfunction) by using Affymetrix miRNA microarray and it was compared with the profile in myocardium of normal mice. The Volcano diagram shows a marked difference in diverse miRNA expression levels (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>Volcano plot of microRNA microarray data of myocardium from obese and normal mice at 16 months. The y-axis values show the negative logarithm base 10 of the P-value. The x-axis is shown as the log 2 differences in estimated relative expression values. The dotted horizontal line on the plot represents the &#x003b1;-level used for this analysis (0.05). Vertical dotted lines represent the threshold for the log 2-fold change (equivalent to a 2-fold change). Thus, the green and red dots correspond to miRNAs that show a significant 4-fold or higher in expression between obese and normal mice (n&#x02009;=&#x02009;3).</p></caption><graphic xlink:href="41598_2017_13875_Fig3_HTML" id="d29e474"/></fig>
</p><p id="Par13">To select the miRNA candidates for RT-qPCR validation, three approaches were considered: (1) statistical criteria: 19 miRNAs were differentially expressed with an FDR of 0.1 and Fold Change (FC)&#x02009;&#x0003e;&#x02009;2 among 3163 miRNA analysed (1908 mature miRNA and 1255 pre-miRNA), see Supplemental Data, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; (2) experimental validated target match: we compared a list of miRNA targets experimentally validated with our list of miRNAs obtained by microarray, finding 17 miRNAs that met this requirement; and (3) biological activity criteria by literature mining. For further details of procedures, see the Methods section.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of MiRNAs gene expression in myocardium from our study respect to previously published data, considering their roles in signalling pathways related to diabetic cardiomyopathy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>microRNAs</th><th>Relative expression (vs. normal mice)</th><th>Biological effect(s) of its regulation previously reported/Signaling pathways and targets involved</th><th>Experimental model/tissue or cell types</th><th>References</th></tr></thead><tbody><tr><td>Let-7f</td><td>&#x02193;</td><td>Alteration of glucose homeostasis and insulin sensitivity/INSR</td><td>C57BL/6 mice feed with high-fat diet (7 weeks)/liver, muscle and pancreas</td><td>
<xref ref-type="bibr" rid="CR20">20</xref>
</td></tr><tr><td>miR-10a</td><td>&#x02193;</td><td>Increase of hyperlipidemic-induced inflammatory response/Rho kinase and connexin43</td><td>Sprague-Dawley rats feed with high-fat diet&#x02009;+&#x02009;streptozotocin /</td><td>
<xref ref-type="bibr" rid="CR21">21</xref>
</td></tr><tr><td>miR-322</td><td>&#x02193;</td><td>Inhibition of the insulin pathway/INRS, IGF1R and cyclin D</td><td>C57BL/6 mice feed with high-fat diet (10 weeks)/heart</td><td>
<xref ref-type="bibr" rid="CR22">22</xref>
</td></tr><tr><td rowspan="2">miR-19b</td><td rowspan="2">&#x02193;</td><td>Inhibition of cell survival pathway</td><td>H9C2 cardiomyocytes culture exposed to H<sub>2</sub>O<sub>2</sub> and neonate rat cardiac fibroblast</td><td>
<xref ref-type="bibr" rid="CR23">23</xref>
</td></tr><tr><td>Inhibition of fibrogenesis pathway/TGF-&#x003b2; RII</td><td>Human cardiac fibroblast cells</td><td>
<xref ref-type="bibr" rid="CR35">35</xref>
</td></tr><tr><td>miR-25</td><td>&#x02193;</td><td>Activation of cell apoptosis related to oxidative stress pathways/MCU</td><td>H9C2 cardiomyocytes culture exposed to doxorubicin</td><td>
<xref ref-type="bibr" rid="CR28">28</xref>
</td></tr><tr><td>miR-199a</td><td>&#x02193;</td><td>Activation of hypoxic response to avoid cell apoptosis/Hif-1&#x003b1; and Sirt1</td><td>Neonatal rat cardiomyocytes</td><td>
<xref ref-type="bibr" rid="CR27">27</xref>
</td></tr><tr><td>miR-30e</td><td>&#x02193;</td><td>Activation of cell apoptosis/Beclin-1</td><td>H9C2 cardiomyocytes culture exposed to doxorubicin</td><td>
<xref ref-type="bibr" rid="CR24">24</xref>
</td></tr><tr><td>miR-140</td><td>&#x02193;</td><td>Activation cell apoptosis/Mitofusin I</td><td>Neonatal rat cardiomyocytes exposed to H<sub>2</sub>O<sub>2</sub>
</td><td>
<xref ref-type="bibr" rid="CR26">26</xref>
</td></tr><tr><td>miR-181a/b</td><td>&#x02193;</td><td>Reduction of basal mitochondrial respiration/Inhibition of PI3K signaling by PTEN increase</td><td>Sponge-H9c2 cardiomyocytes culture</td><td>
<xref ref-type="bibr" rid="CR29">29</xref>
</td></tr><tr><td>miR-499</td><td>&#x02193;</td><td>Activation cell apoptosis/Pdcd4, Pacs2 and Dyrk2</td><td>H9C2 cardiomyocytes culture exposed to H<sub>2</sub>O<sub>2</sub>
</td><td>
<xref ref-type="bibr" rid="CR25">25</xref>
</td></tr><tr><td>miR-146a</td><td>&#x02193;</td><td>Activation of inflammatory genes, fibronectin, MMPs and collagen via Fos - AP1</td><td>AC16 cell line (cardiac muscle cells)</td><td>
<xref ref-type="bibr" rid="CR30">30</xref>
</td></tr><tr><td>miR-155</td><td>&#x02193;</td><td>Activation of inflammatory signalling pathways/NF-kB</td><td>Diabetes Mellitus type 1 model with Sprague-Dawley rats administrated with streptozotocin</td><td>
<xref ref-type="bibr" rid="CR31">31</xref>
</td></tr><tr><td>miR-3473b</td><td>&#x02193;</td><td>Activation of inflammatory signalling pathways/TRAF3 - NF-kB</td><td>Bacterial infection model with Murine macrophages</td><td>
<xref ref-type="bibr" rid="CR33">33</xref>
</td></tr><tr><td>miR-451</td><td>&#x02193;</td><td>It upregulation induces activation of lipotoxicity through suppression of the LKB1/AMPK pathway</td><td>C57BL/6 mice feed with high fat diet (20 weeks)/heart; Neonatal rat cardiomyocytes</td><td>
<xref ref-type="bibr" rid="CR34">34</xref>
</td></tr></tbody></table><table-wrap-foot><p>AP-1: Activator protein 1, AMPK: AMP-activated protein kinase, Dyrk2: Dual specificity tyrosine-phosphorylation-regulated kinase 2, INRS: Insulin receptor, IGF1R: Insulin growth factor 1 receptor, LKB1: Liver kinase B1, MCU: Mitocondrial calcium uniporter, MMP: Matrix metalloproteinase, NF-&#x003ba;B: Nuclear factor &#x003ba;B, Pacs2: Phosphofurin acidic cluster sorting protein 2, PTEN: phosphatase and tensin homolog; Pdcd4: programmed cell death 4, Sirt1 Sirtuin 1, TGF-&#x003b2; RII: transforming growth factor beta receptor II, TRAF3: TNF Receptor associated factor 3.</p></table-wrap-foot></table-wrap>
</p><p id="Par14">A total of 15 miRNAs (let-7f-5p, miR-10a-5p, miRNA-19b-3p, miR-25-3p, miR30e-5p, miR-140-5p, miR-155-5p, miR-146a-5p, miR-181b-5p, miR-199a-3p, miR-322, miR-451, miR-499-5p, miR-669m-5p and miR-3473b) were selected considering the three approaches.</p><p id="Par15">A summary of validation data of differential expression of miRNAs in the myocardium of obese compared to normal mice at 4 and 16 months is showed in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. For normalization procedure, snoRNA202 was used as an endogenous control. At 16 months, all 15 miRNAs were significantly downregulated in heart tissue of obese mice compared to heart tissue of normal mice: let-7f-5p (FC: 3.3), miR-10a-5p (FC: 2.6), miRNA-19b-3p (FC: 5.0), miR-25-3p (FC: 2.6), miR30e-5p (FC: 5.6), miR-140-5p (FC: 5.0), miR-155-5p (FC: 1.7), miR-146a-5p (FC: 4.0), miR-181b-5p (3.0), miR-199a-3p (FC: 3.6), miR-322 (FC: 1.5), miR-451 (FC: 1.9), miR-499-5p (FC: 5.4), miR-669m-5p (FC: 1.7) and miR-3473b (FC: 3.4). At 4 months of high-fat diet feeding, 3 miRNAs were upregulated: let7f-5p (FC: 2.3), miR-140-5p (FC: 3.8) and miR-199-3p (FC: 2.1), but two miRNAs were down regulated in obese mice with respect to normal mice: miR-155 (FC: 1.7) and miR-322 (FC: 1.5). The gene expression of the remaining miRNAs was unchanged within both experimental groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Figure 4</label><caption><p>Validation of the differentially expressed miRNAs in myocardium by RT-qPCR. MiRNAs were isolated from myocardium of normal and obese mice after 4 and 16 months of dietary treatment. Solid and dotted lines indicate normal and obese mice respectively. Relative expression of each miRNA was normalized to snoRNA202. (n&#x02009;=&#x02009;8&#x02013;9). Mean&#x02009;&#x000b1;&#x02009;SEM, *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01 vs. normal mice (Two-way ANOVA test).</p></caption><graphic xlink:href="41598_2017_13875_Fig4_HTML" id="d29e832"/></fig>
</p></sec><sec id="Sec5"><title>MiRNA differentially expressed in plasma during diabetic cardiomyopathy progression</title><p id="Par16">In order to select the miRNAs in which plasmatic levels may reflect changes in gene expression in myocardium, we first determined the miRNA relative abundance in plasma of obese and normal mice at 16 months, considering the cel-miR-39 as a spike-in for their miRNA levels normalization (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). We found 8 circulating miRNAs that were less abundant in the obese mice than in normal mice, indicating an association between their gene expression in myocardium: let-7f-5p (FC: 5.4), miR-10a-5p (FC: 2.3), miRNA-19b-3p (FC: 2.5), miR-25-3p (FC: 3.4), miR-140-5p (FC: 4.5), miR-146a-5p (FC: 3.3), miR-181b-5p (FC: 5.2) and miR-499-5p (FC: 2.2). Then, we performed a time-course study, measuring these miRNA levels in plasma at 4 and 12 months retrospectively to detect changes in their levels before cardiac dysfunction manifestation. At 12 months we observed a reduction of their abundance in 4 circulating miRNAs: miR-25-3p (FC: 1.5), let-7f-5p (FC: 5.2), miR-181b-5p (FC: 2.0) and miR-19b-3p (FC: 3.4); plasmatic levels were reduced in obese mice during the dietary treatment (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). However, only in the last two miRNAs were the differences with respect to normal mice statistically significant (p&#x02009;&#x0003c;&#x02009;0.04 and p&#x02009;&#x0003c;&#x02009;0.03 respectively), suggesting that both miRNAs could be useful as biomarkers for diabetic cardiomyopathy. Interestedly, at 4 months, miR-140-5p plasmatic levels were higher in obese mice than in the normal mice (FC: 3.6), according to data obtained from myocardium expression experiments (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig5"><label>Figure 5</label><caption><p>Circulating miRNAs in plasma at 16 months. MiRNAs were assessed at 16 months of dietary treatment. Relative abundance of each miRNA was normalized to cel-miR-39. (n&#x02009;=&#x02009;8&#x02013;9). Mean&#x02009;&#x000b1;&#x02009;SEM, *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01 vs. normal mice (Mann-Whitney test).</p></caption><graphic xlink:href="41598_2017_13875_Fig5_HTML" id="d29e856"/></fig>
<fig id="Fig6"><label>Figure 6</label><caption><p>Circulating miRNAs in plasma. MiRNAs were assessed at 4, 12 and 16 months of dietary treatment. Solid and dotted lines indicate normal and obese mice respectively. Relative abundance of each miRNA was normalized to cel-miR-39. (n&#x02009;=&#x02009;8&#x02013;9). Mean&#x02009;&#x000b1;&#x02009;SEM, *p&#x02009;&#x0003c;&#x02009;0.05 vs. normal mice (Two way ANOVA, Tukey HSD).</p></caption><graphic xlink:href="41598_2017_13875_Fig6_HTML" id="d29e866"/></fig>
</p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par17">In the present study, we defined three time-points in the development of diabetic cardiomyopathy induced by high-fat diet feeding: an initial stage with metabolic syndrome manifestations and cardiac hypertrophy with normal arterial pressure and cardiac function (4 months); a &#x0201c;subclinical&#x0201d; stage in which cardiac dysfunction is detectable only under stress test condition (12 months); and a last stage in which heart function is decreased at basal condition in obese mice with normal arterial pressure but significant cardiac hypertrophy, which are characteristics of early diabetic cardiomyopathy (16 months)<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. In previous works, the induction of obesity by high-fat diet did not extend much longer than 5 months, in order to study its effect on cardiac metabolism and function, observing cardiac hypertrophy (as in this study) and a slight cardiac dysfunction in obese mice (C57BL/6 strain) measured by echocardiography<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. On the other hand, according to our results, a recent study described that high-fat diet feeding for 7 months did not alter cardiac function measuring by echocardiography in the same mice strain<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. An explanation for the differences in cardiac susceptibility to high fat diet between published studies could be due to the use of different substrains of C57BL/6<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>.</p><p id="Par18">We found differential expression of several miRNAs in myocardium of mice with diabetic cardiomyopathy compared to that of normal mice. A recent study demonstrated that high-fat diet feeding after five months induced a different miRNA expression pattern in the heart, identifying miR-21a-3p, miR-29c-3p, and miR-195a-3p related to the glucose metabolic pathway<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. We found the same miRNAs deregulated negatively in obese mice in the microarray study at 16 months, associated to the metabolic syndrome description of hyperglycaemia and glucose intolerance (Table&#x000a0;<xref rid="MOESM1" ref-type="media">1S</xref>)<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p><p id="Par19">We clearly observed three different miRNA expression patterns in myocardium during the dietary treatment: (1) an initial upregulation of miRNAs expression at 4 months, but their expression was reduced significantly in obese mice during the heart dysfunction development; (2) unchanged miRNAs expression in obese mice at 4 months, with an evident reduction of their expression at 16 months; and, finally, (3) a visible reduction of miRNAs expression in obese mice at 4 months that remained until the end of the study. Based on previous pre-clinic studies, the miRNAs validated by RT-qPCR in our study are involved in alteration of glucose and lipid metabolism via insulin pathways (let-7f-5p, miR-10a-5p, miR-322)<sup><xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup>, in cardiomyocytes apoptosis (miR-19b-3p, miR-25-3p, miR-30e-5p, miR-140-5p, miR-199a-3p, miR-499)<sup><xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref></sup>, in mitochondrial function (miR-181a/b)<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, in pro-inflammatory signalling (miR-146a-5p, miR-155, miR-181b-3p, miR-3473b)<sup><xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref></sup>, and in cardiac hypertrophy (miR-451)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> and myocardial fibrosis process (miR-19b)<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Experimental details are described in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> where we summarize a selection of studies whose results suggested a role of selected miRNAs in our animal model of diabetic cardiomyopathy.</p><p id="Par20">Regarding the role of miR-19b in diabetic cardiomyopathy, Costantino and colleagues reported that miR-19b expression is up-regulated in myocardium of diabetic mice induced by streptozotocin administration (type I diabetes mellitus)<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. On the contrary, we found miR-19b was downregulated in obese mice. Bugger and colleagues reported differences in the cardiac energetic metabolism between type 1 and type 2 diabetes animal models (induced by high-fat diet)<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. We suggest that different sources of metabolic dysregulation may explain the observed differences in miR-19b expression levels between type 1 and type 2 diabetes animal models. On the other hand, miR-181b myocardial expression was not associated with cardiac dysfunction in diabetic cardiomyopathy animal models. However, recent works suggest that miR-181b may have a central role in vascular inflammation, inhibiting the activation of NF-&#x003ba;B signalling in endothelial cells<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Hori D and colleagues demonstrated that age-dependent decrease of miR-181b plays a critical role in vascular remodelling by activating TGF-&#x003b2;/pSmadD2/3 pathways<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. In addition, miR-181b expression was markedly reduced in cardiac fibroblasts in response to Angiotensin II, suggesting its potential role in cardiac fibrosis<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Regarding insulin resistance mechanisms, Sun and colleagues reported that gene expression of miR-181b was decreased in adipose tissue and endothelial cells of obese mice, impairing glucose homeostasis, insulin sensitivity and promoting adipose tissue inflammation<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>.</p><p id="Par21">Regarding circulating miRNAs as potential biomarkers of diabetic cardiomyopathy, we found an association between differential miRNA expressions in myocardium and plasma at 16 months in 8 miRNAs (let-7f-5p, miR-10a-5p, miR-19b-3p, miR-25-3p, miR-140-5p, miR-146a-5p, miR-181b-5p, miR-499-5p). To date, many clinical trials have proposed various circulating miRNAs as biomarkers for diabetes prognosis<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. It was demonstrated that diabetic patients have a reduction of circulating let-7f-5p levels with respect to healthy individuals, but the concentration increases again with an anti-diabetic treatment<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Looking for pre-diabetes biomarkers, Nunez Lopez and colleagues identified a set of miRNAs, including miR-146a, that enable a classification to be made between lean, obese, and pre-diabetic patients<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Using a DM type 2 animal model (Zucker diabetic fatty rat), Delic and colleagues reported that circulating miR-140 decreases during the progression of diabetes<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, propounding it as a potential biomarker for early manifestation of this disease. The biomarker properties of circulating miRNAs have been studied in cardiac diseases, in particular in the diagnosis of myocardial infarction<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Recently, Zhang and colleagues reported that plasma miR-499 increase is detectable as early as 1&#x02009;h after onset of chest pain in acute myocardial infarction, proposing it as a sensitive biomarker for early diagnosis of a cardiac ischemic event<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. These data coincide with previous results where it showed that miR-499 levels were increased in failing and hypertrophied human hearts, and in animal models of cardiac hypertrophy by miR-499 overexpression<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. In our obese animal model, cardiac hypertrophy is present in spite of miR-499 being down regulated, showing that miR-208a/miR-499 pathway is not the driving force to generate the increase of heart mass and leaving open this possibility to other signal pathways like IGF-1, TGF-&#x003b2; or inflammatory cytokines related to diabetic cardiomyopathy (Table&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>)<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. The circulating miR-10a-5p was proposed as a non-invasive biomarker of transplant rejection in heart transplant recipients<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, indicating worse prognosis and a reduction of its level in plasma. Fang and colleagues demonstrated that 16 miRNAs, including miR-19b serve as potential biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy with aortic stenosis and heart<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. In addition, Karakas and colleagues showed that miR-19b could be a useful tool to predict cardiovascular mortality in patients diagnosed with stable angina pectoris or acute coronary syndrome in a prognostic study with a median follow-up of 4 years<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Seeger and colleagues reported that a decrease of miR-181b and miR-181c levels in serum correlate with changes in the course of immune-senescence accentuated in chronic heart failure patients, providing evidence for miR-181c as a biomarker of poor prognosis in patients with ischaemic or dilated cardiomyopathy<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Taking into account these previous studies about miR-19b and miR-181b as biomarkers in cardiac disease, we suggest the validation of their utilization as biomarkers for diabetic cardiomyopathy in a specific group of patients diagnosed with asymptomatic diabetes (related to obesity) without pre-existing coronary arterial disease in the context of primary prevention of cardiovascular disease.</p><p id="Par22">In conclusion, we propose miR-19b and miR-181b as potential biomarkers for diabetic cardiomyopathy, with eventual application in clinical diagnosis to prevent metabolic and functional alteration in hearts of asymptomatic diabetic patients.</p></sec><sec id="Sec7" sec-type="materials|methods"><title>Methods</title><sec id="Sec8"><title>Animals</title><p id="Par23">C57BL/6 male mice were housed at constant temperature (22&#x02009;&#x000b1;&#x02009;2&#x02009;&#x000b0;C) and humidity (60%), with a 12:12&#x02009;hours light:dark cycle and unrestricted access to food and water.</p><p id="Par24">Diabetic cardiomyopathy induction: All mice were fed with a regular diet up to and until five weeks of age. Then, they were kept on a regular diet (normal) or switched to high-fat diet (obese) until the end of the study (16 months of tested diet). Regular diet corresponded to 10&#x02009;cal% fat, 20&#x02009;cal% proteins and 70&#x02009;cal% carbohydrates (Champion SA, Chile). High-fat diet corresponded to 60&#x02009;cal% fat, 20&#x02009;cal% proteins and 20&#x02009;cal% carbohydrates (D12492, Research Diets Inc., USA). Animals were weighed weekly.</p><p id="Par25">Animal experiments were performed in accordance with the Guide for Care and Use of Laboratory Animals<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> and were approved by the Animal Care and Use Committee of the Faculty of Medicine, Cl&#x000ed;nica Alemana-Universidad del Desarrollo.</p></sec><sec id="Sec9"><title>Plasma glucose and NEFAs quantification</title><p id="Par26">After six hours of fasting, blood samples were collected from the tail vein of alert mice. Plasma glucose levels were determined with the glucometer system Accu-Chek Performa (Roche Diagnostic, Germany). Plasma NEFA levels were measured using the Free Fatty Acid quantitation kit, (Sigma-Aldrich, USA).</p></sec><sec id="Sec10"><title>Glucose tolerance test</title><p id="Par27">After six hours of fasting, mice received intraperitoneally 2&#x02009;mg D-glucose/g body weight. Fifteen minutes before and 15, 30, 60, 90 and 120&#x02009;minutes after D-glucose administration, blood glucose quantification was performed according with the method above described.</p></sec><sec id="Sec11"><title>Cardiovascular parameter assessment at basal and stress conditions</title><p id="Par28">Mice were deeply anesthetized with 60&#x02009;mg/Kg ketamine plus 4&#x02009;mg/Kg xylazine and placed in supine position on a thermo-regulated plate. Body temperature was monitored using a rectal thermometer and gaseous oxygen was supplied. Hemodynamic parameters were measured by cardiac catheterization<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>. The catheter consisted of a Mikro-Tip SPR-671 pressure sensor (Millar, USA), which was coupled to the PCU-2000 transducer pressure/volt (Millar) and connected to the PowerLab 4/30 data acquisition system (AdInstruments, Australia). Hemodynamic parameters (arterial systolic and diastolic pressures, mean arterial pressure (MAP), Left ventricular end-diastolic pressure, (LVEDP), <italic>d</italic>P/<italic>d</italic>t<sub>max</sub> and <italic>d</italic>P/<italic>d</italic>t<sub>min</sub>) were recorded under basal and stress conditions. For the latter, a PE-10 plastic tube (Warner Instruments Company, USA) was introduced into the mice jugular vein and connected to a KDS-KDS210P pump (Kdscientific Inc., USA) for dobutamine stimulation. The dobutamine infusion regime consisted of six, two-minute intervals, from 2 ng/g/min to 12 ng/g/min<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Data obtained were analysed with LabChart 7Pro software (AdInstruments, Australia).</p></sec><sec id="Sec12"><title>Cardiac macroscopic analysis</title><p id="Par29">After the cardiac catheterization study, mice were euthanized with an overdose of ketamine/xylazine (60/4&#x02009;mg/Kg) and hearts were removed. Heart samples were cryopreserved at &#x02212;80&#x02009;&#x000b0;C for miRNA analysis.</p></sec><sec id="Sec13"><title>Total RNA isolation</title><p id="Par30">Frozen heart samples (50&#x02009;mg approximately) were homogenised by pellet pestle (Sigma-Aldrich, USA). Blood was obtained by cardiac puncture and collected in a tube containing EDTA as anticoagulant. A volume of 300&#x02009;&#x003bc;l of plasma was considered for each sample. Total RNA was extracted using miRVana PARIS (Applied Biosystems, USA) according to the manufacturer&#x02019;s instructions. After the denaturation step, 0.6 fmol of Cel-miR-39 in 2&#x02009;&#x003bc;l nuclease-free water was added. RNAs were eluted in free-nuclease-free water and frozen at &#x02212;80&#x02009;&#x000b0;C. RNA quality was assessed using the 2200 TapeStation System (Agilent Technologies, USA). Samples with a RIN (RNA integrity number) more than 7 were considered for further experiments.</p></sec><sec id="Sec14"><title>Microarray of microRNA</title><p id="Par31">MiRNA expression patterns were examined by GeneChip miRNA 4.0 arrays (Affymetrix, USA), which was designed based on miRBase version 20. The array included 1908 probes for mature microRNAs and 1255 for pre-mature microRNAs. One microgram of total RNA was used as input into the labelling reaction as recommended by the protocol of the FlashTag Biotin HSR RNA Labelling Kit (Affymetrix, USA). Labelled miRNA was then hybridized to the array for 16&#x02009;hours at 48&#x02009;&#x000b0;C and 60&#x02009;rpm. Then Genechips were scanned by using the GeneChip Scanner 3000 7&#x02009;G (Affymetrix, USA).</p></sec><sec id="Sec15"><title>Microarray data analysis</title><p id="Par32">CEL files were normalized using the RMA algorithm. Differentially expressed genes were identified using the t-test in TAC software (Affymetrix) by using an FDR value threshold of (&#x0003c;0.1) and an absolute fold-change&#x02009;&#x0003e;&#x02009;2.</p></sec><sec id="Sec16"><title>Mapping miRNA to known pathways</title><p id="Par33">In order to increase the power of the microarray analysis, the integrated information on validated miRNA-target interactions on KEGG pathways from miRWalk 2.0 was used. First, we used a less stringent criterion for selecting miRNAs for the microarray analysis. In this context, we used raw p-value of 0.05 as a threshold, selecting 94 miRNAs.</p><p id="Par34">The MiRWalk2.0 database contains interactions of miRNA-targets of genes related to the specific process. KEGG pathways related to the experimental design were selected in order to obtain the interactions previously identified. The selected pathways were: &#x0201c;Apoptosis&#x0201d;, mmu04210; &#x0201c;Cardiac muscle contraction&#x0201d;, mmu04260; &#x0201c;Hypertrophic cardiomyopathy&#x0201d;, mmu05410; &#x0201c;Insulin signalling pathway&#x0201d;, mmu04910; and Type II diabetes mellitus, mmu04930. The miRNAs obtained from these KEGG pathways were matched with those from the list of selected miRNAs.</p></sec><sec id="Sec17"><title>RT-qPCR for microRNA expression</title><p id="Par35">cDNA from isolated miRNA of myocardium and plasma were synthetized using the cDNA Taqman<sup>&#x000ae;</sup> miRNA Reverse Transcription kit or TaqMan<sup>&#x000ae;</sup> Advanced miRNA cDNA Synthesis Kit. Synthesized cDNA samples were then subjected to RT-qPCR using the TaqMan<sup>&#x000ae;</sup> Universal PCR Master Mix II, No UNG or TaqMan<sup>&#x000ae;</sup> Advanced miRNA Assays according to the manufacturer&#x02019;s instructions (Applied Biosystems). The IDs of the probes are: 478139_mir, miR-499-5p; 465329_mat, miR-669m-5p; 001076, miR-322; 465212_mat, miR-3473b; 479241_mir, miR-10a-5p; 478583_mir, 181b-5p; 002571, miR-155-5p; 478399_mir, miR-146a-5p; 002562, miR-541; 001141, miR-451; 479235_mir, miR30e-5p; 478264_mir, miRNA-19b-3p; 478578_mir, let-7f-5p; 477909_mir, miR-140-5p; 477961_mir, miR-199a-3p; 477994_mir, miR-25-3p; 478293_mir, cel-miR-39-3p; 001973, U6 snRNA; 1232, snoRNA202 and 1234, snoRNA234.</p><p id="Par36">Expression levels between normal and obese mice were quantitatively compared using the &#x00394;&#x00394;Ct method. The snoRNA202, snoRNA234 and U6 snRNA expression were analysis by NormFinder to choose the most suitable candidate to use it as an endogenous control in myocardium and cel-miR-39 as a spike-in miRNA for miRNA abundance normalization in plasma.</p></sec><sec id="Sec18"><title>Statistical analysis</title><p id="Par37">Data presented as mean&#x02009;&#x000b1;&#x02009;S.E.M. Normal distribution was tested by using the Kolmogorov-Smirnov test. To determine the statistical significances of intergroup differences, a two-way ANOVA test was used to compare mean values among all groups and Student&#x02019;s unpaired <italic>t</italic>-test or Mann-Whitney test (non-parametric) was used to compare mean values between the two groups. Except for the microarray study, sample size as estimated considering a 5% of significance level and 80% of statistical power as described<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. p&#x02009;&#x0003c;&#x02009;0.05 was considered as statistically significant. GraphPad Prism version 4.03 software was used. For plasmatic miRNA levels comparison, we used a two ANOVA model followed with TukeyHSD post test in R software 3.4 version. MiRNA expression stability was determined using the NormFinder Visual Basic application for Microsoft Excel<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>.</p></sec></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec19"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2017_13875_MOESM1_ESM.pdf"><caption><p>Supplementary materials</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41598_2017_13875_MOESM2_ESM.xls"><caption><p>miR-19b and miR-181b gene targerts</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41598_2017_13875_MOESM3_ESM.zip"><caption><p>miRNA Microarray Raw data</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>Camila Uribe Copier and Luis Le&#x000f3;n contributed equally to this work.</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p>
<bold>Supplementary information</bold> accompanies this paper at 10.1038/s41598-017-13875-2.</p></fn><fn><p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Dr. J. Urzua for his kind support in the early stage of this project. This project was supported by a grant from the Chilean Ministry of Education: Proyecto Mineduc - UDD PMI 1204 &#x0201c;De la ciencia a la innovaci&#x000f3;n en salud: adopci&#x000f3;n en la actividad cl&#x000ed;nica, nacional e internacional, de nuevos productos, procesos y pr&#x000e1;cticas de clase mundial, basados en investigaci&#x000f3;n cient&#x000ed;fica de la UDD y de terceros&#x0201d;.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Idea and design: L.L., S.C., M.F.; collection data: C.U., S.C., D.C., L.L.; data analysis and interpretation: C.U., S.C., D.C., L.L.; writing of the draft of the article: S.C., L.L., C.U. and critical review of article: C.U., S.C., D.C., L.L., M.F.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p id="Par38">The authors declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Global Report on Diabetes. (World Health Organization, 2016).</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubler</surname><given-names>S</given-names></name><etal/></person-group><article-title>New type of cardiomyopathy associated with diabetic glomerulosclerosis</article-title><source>Am J Cardiol</source><year>1972</year><volume>30</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(72)90595-4</pub-id><?supplied-pmid 4263660?><pub-id pub-id-type="pmid">4263660</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boudina</surname><given-names>S</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><article-title>Diabetic cardiomyopathy, causes and effects</article-title><source>Rev Endocr Metab Disord</source><year>2010</year><volume>11</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s11154-010-9131-7</pub-id><?supplied-pmid 20180026?><pub-id pub-id-type="pmid">20180026</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>S</given-names></name><name><surname>Canpolat</surname><given-names>U</given-names></name><name><surname>Aydogdu</surname><given-names>S</given-names></name><name><surname>Abboud</surname><given-names>HE</given-names></name></person-group><article-title>Diabetic Cardiomyopathy; Summary of 41 Years</article-title><source>Korean Circ J</source><year>2015</year><volume>45</volume><fpage>266</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.4070/kcj.2015.45.4.266</pub-id><?supplied-pmid 26240579?><pub-id pub-id-type="pmid">26240579</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandamudi</surname><given-names>S</given-names></name><etal/></person-group><article-title>The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota</article-title><source>J Card Fail</source><year>2014</year><volume>20</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2014.02.007</pub-id><?supplied-pmid 24576788?><pub-id pub-id-type="pmid">24576788</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiencke</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome</article-title><source>Eur J Heart Fail</source><year>2010</year><volume>12</volume><fpage>951</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfq110</pub-id><?supplied-pmid 20581103?><pub-id pub-id-type="pmid">20581103</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavali</surname><given-names>V</given-names></name><name><surname>Tyagi</surname><given-names>SC</given-names></name><name><surname>Mishra</surname><given-names>PK</given-names></name></person-group><article-title>Predictors and prevention of diabetic cardiomyopathy</article-title><source>Diabetes Metab Syndr Obes</source><year>2013</year><volume>6</volume><fpage>151</fpage><lpage>160</lpage><?supplied-pmid 23610527?><pub-id pub-id-type="pmid">23610527</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teupe</surname><given-names>C</given-names></name><name><surname>Rosak</surname><given-names>C</given-names></name></person-group><article-title>Diabetic cardiomyopathy and diastolic heart failure&#x02013;difficulties with relaxation</article-title><source>Diabetes Res Clin Pract</source><year>2012</year><volume>97</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2012.03.008</pub-id><?supplied-pmid 22502812?><pub-id pub-id-type="pmid">22502812</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuermann</surname><given-names>JC</given-names></name><name><surname>Boyer</surname><given-names>LA</given-names></name></person-group><article-title>Getting to the heart of the matter: long non-coding RNAs in cardiac development and disease</article-title><source>Embo J</source><year>2013</year><volume>32</volume><fpage>1805</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.134</pub-id><?supplied-pmid 23756463?><pub-id pub-id-type="pmid">23756463</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Gonzalo-Calvo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>37354</fpage><pub-id pub-id-type="doi">10.1038/srep37354</pub-id><?supplied-pmid 27874027?><pub-id pub-id-type="pmid">27874027</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barwari</surname><given-names>T</given-names></name><name><surname>Joshi</surname><given-names>A</given-names></name><name><surname>Mayr</surname><given-names>M</given-names></name></person-group><article-title>MicroRNAs in Cardiovascular Disease</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>68</volume><fpage>2577</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.09.945</pub-id><?supplied-pmid 27931616?><pub-id pub-id-type="pmid">27931616</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>VS</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Tewari</surname><given-names>M</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group><article-title>Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies</article-title><source>Am J Epidemiol</source><year>2014</year><volume>180</volume><fpage>140</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1093/aje/kwu135</pub-id><?supplied-pmid 24966218?><pub-id pub-id-type="pmid">24966218</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calligaris</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Mice long-term high-fat diet feeding recapitulates human cardiovascular alterations: an animal model to study the early phases of diabetic cardiomyopathy</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e60931</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0060931</pub-id><?supplied-pmid 23593350?><pub-id pub-id-type="pmid">23593350</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Hu, N. &#x00026; Zhang, Y. TLR4 Knockout Attenuated High Fat Diet-Induced Cardiac Dysfunction via NF-kappaB/JNK-Dependent Activation of Autophagy. <italic>Biochim Biophys Acta</italic>, doi:10.1016/j.bbadis.2017.01.010 (2017).</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Vaka</surname><given-names>VR</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Booz</surname><given-names>GW</given-names></name><name><surname>Chen</surname><given-names>JX</given-names></name></person-group><article-title>High-fat diet induces cardiac remodelling and dysfunction: assessment of the role played by SIRT3 loss</article-title><source>J Cell Mol Med</source><year>2015</year><volume>19</volume><fpage>1847</fpage><lpage>1856</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12556</pub-id><?supplied-pmid 25782072?><pub-id pub-id-type="pmid">25782072</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brainard</surname><given-names>RE</given-names></name><etal/></person-group><article-title>High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e83174</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0083174</pub-id><?supplied-pmid 24367585?><pub-id pub-id-type="pmid">24367585</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>DM</given-names></name><name><surname>Swaney</surname><given-names>JS</given-names></name><name><surname>Dalton</surname><given-names>ND</given-names></name><name><surname>Gilpin</surname><given-names>EA</given-names></name><name><surname>Ross</surname><given-names>J</given-names><suffix>Jr.</suffix></name></person-group><article-title>Impact of anesthesia on cardiac function during echocardiography in mice</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2002</year><volume>282</volume><fpage>H2134</fpage><lpage>2140</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00845.2001</pub-id><?supplied-pmid 12003821?><pub-id pub-id-type="pmid">12003821</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hull</surname><given-names>RL</given-names></name><etal/></person-group><article-title>High fat feeding unmasks variable insulin responses in male C57BL/6 mouse substrains</article-title><source>J Endocrinol</source><year>2017</year><volume>233</volume><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1530/JOE-16-0377</pub-id><?supplied-pmid 28138002?><pub-id pub-id-type="pmid">28138002</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guedes</surname><given-names>EC</given-names></name><etal/></person-group><article-title>MicroRNA Expression Signature Is Altered in the Cardiac Remodeling Induced by High Fat Diets</article-title><source>J Cell Physiol</source><year>2016</year><volume>231</volume><fpage>1771</fpage><lpage>1783</lpage><pub-id pub-id-type="doi">10.1002/jcp.25280</pub-id><?supplied-pmid 26638879?><pub-id pub-id-type="pmid">26638879</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>RJ</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name></person-group><article-title>Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>21075</fpage><lpage>21080</lpage><pub-id pub-id-type="doi">10.1073/pnas.1118922109</pub-id><?supplied-pmid 22160727?><pub-id pub-id-type="pmid">22160727</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway</article-title><source>Am J Physiol Endocrinol Metab</source><year>2015</year><volume>308</volume><fpage>E257</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00348.2014</pub-id><?supplied-pmid 25425000?><pub-id pub-id-type="pmid">25425000</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchand</surname><given-names>A</given-names></name><etal/></person-group><article-title>miR-322 regulates insulin signaling pathway and protects against metabolic syndrome-induced cardiac dysfunction in mice</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1862</volume><fpage>611</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2016.01.010</pub-id><?supplied-pmid 26775030?><pub-id pub-id-type="pmid">26775030</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>C</given-names></name><etal/></person-group><article-title>miR-19b controls cardiac fibroblast proliferation and migration</article-title><source>J Cell Mol Med</source><year>2016</year><volume>20</volume><fpage>1191</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1111/jcmm.12858</pub-id><?supplied-pmid 27061862?><pub-id pub-id-type="pmid">27061862</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Lai, L., Wang, N., Zhu, G., Duan, X. &#x00026; Ling, F. MiRNA-30e mediated cardioprotection of ACE2 in rats with doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy. <italic>Life Sci</italic>, doi:10.1016/j.lfs.2016.09.006 (2016).</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group><article-title>miR-499 protects cardiomyocytes from H 2O 2-induced apoptosis via its effects on Pdcd4 and Pacs2</article-title><source>RNA Biol</source><year>2014</year><volume>11</volume><fpage>339</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.4161/rna.28300</pub-id><?supplied-pmid 24646523?><pub-id pub-id-type="pmid">24646523</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Mitofusin 1 is negatively regulated by microRNA 140 in cardiomyocyte apoptosis</article-title><source>Mol Cell Biol</source><year>2014</year><volume>34</volume><fpage>1788</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1128/MCB.00774-13</pub-id><?supplied-pmid 24615014?><pub-id pub-id-type="pmid">24615014</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rane</surname><given-names>S</given-names></name><etal/></person-group><article-title>Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes</article-title><source>Circ Res</source><year>2009</year><volume>104</volume><fpage>879</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.193102</pub-id><?supplied-pmid 19265035?><pub-id pub-id-type="pmid">19265035</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L</given-names></name><etal/></person-group><article-title>MiR-25 protects cardiomyocytes against oxidative damage by targeting the mitochondrial calcium uniporter</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><fpage>5420</fpage><lpage>5433</lpage><pub-id pub-id-type="doi">10.3390/ijms16035420</pub-id><?supplied-pmid 25764156?><pub-id pub-id-type="pmid">25764156</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Das, S. <italic>et al</italic>. Divergent Effects of miR-181 Family Members on Myocardial Function Through Protective Cytosolic and Detrimental Mitochondrial microRNA Targets. <italic>J Am Heart Assoc</italic><bold>6</bold>, doi:10.1161/JAHA.116.004694 (2017).</mixed-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomer</surname><given-names>X</given-names></name><etal/></person-group><article-title>miR-146a targets Fos expression in human cardiac cells</article-title><source>Dis Model Mech</source><year>2015</year><volume>8</volume><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1242/dmm.020768</pub-id><?supplied-pmid 26112171?><pub-id pub-id-type="pmid">26112171</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khamaneh</surname><given-names>AM</given-names></name><name><surname>Alipour</surname><given-names>MR</given-names></name><name><surname>Sheikhzadeh Hesari</surname><given-names>F</given-names></name><name><surname>Ghadiri Soufi</surname><given-names>F</given-names></name></person-group><article-title>A signature of microRNA-155 in the pathogenesis of diabetic complications</article-title><source>J Physiol Biochem</source><year>2015</year><volume>71</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1007/s13105-015-0413-0</pub-id><?supplied-pmid 25929727?><pub-id pub-id-type="pmid">25929727</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Sit</surname><given-names>A</given-names></name><name><surname>Feinberg</surname><given-names>MW</given-names></name></person-group><article-title>Role of miR-181 family in regulating vascular inflammation and immunity</article-title><source>Trends Cardiovasc Med</source><year>2014</year><volume>24</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2013.09.002</pub-id><?supplied-pmid 24183793?><pub-id pub-id-type="pmid">24183793</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Burkholderia pseudomallei-derived miR-3473 enhances NF-kappaB via targeting TRAF3 and is associated with different inflammatory responses compared to Burkholderia thailandensis in murine macrophages</article-title><source>BMC Microbiol</source><year>2016</year><volume>16</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.1186/s12866-016-0901-6</pub-id><?supplied-pmid 27894256?><pub-id pub-id-type="pmid">27894256</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwabara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway</article-title><source>Circ Res</source><year>2015</year><volume>116</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.304707</pub-id><?supplied-pmid 25362209?><pub-id pub-id-type="pmid">25362209</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autophagy inhibition of hsa-miR-19a-3p/19b-3p by targeting TGF-beta R II during TGF-beta1-induced fibrogenesis in human cardiac fibroblasts</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>24747</fpage><pub-id pub-id-type="doi">10.1038/srep24747</pub-id><?supplied-pmid 27098600?><pub-id pub-id-type="pmid">27098600</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantino</surname><given-names>S</given-names></name><name><surname>Paneni</surname><given-names>F</given-names></name><name><surname>Luscher</surname><given-names>TF</given-names></name><name><surname>Cosentino</surname><given-names>F</given-names></name></person-group><article-title>MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv599</pub-id><?supplied-pmid 26553540?><pub-id pub-id-type="pmid">26553540</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugger</surname><given-names>H</given-names></name><etal/></person-group><article-title>Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2924</fpage><lpage>2932</lpage><pub-id pub-id-type="doi">10.2337/db08-0079</pub-id><?supplied-pmid 18678617?><pub-id pub-id-type="pmid">18678617</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>D</given-names></name><etal/></person-group><article-title>miR-181b regulates vascular stiffness age dependently in part by regulating TGF-beta signaling</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0174108</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0174108</pub-id><?supplied-pmid 28323879?><pub-id pub-id-type="pmid">28323879</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Angiotensin II induced differentially expressed microRNAs in adult rat cardiac fibroblasts</article-title><source>J Physiol Sci</source><year>2013</year><volume>63</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s12576-012-0230-y</pub-id><?supplied-pmid 23007623?><pub-id pub-id-type="pmid">23007623</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>MicroRNA-181b Improves Glucose Homeostasis and Insulin Sensitivity by Regulating Endothelial Function in White Adipose Tissue</article-title><source>Circ Res</source><year>2016</year><volume>118</volume><fpage>810</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.308166</pub-id><?supplied-pmid 26830849?><pub-id pub-id-type="pmid">26830849</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Leung</surname><given-names>SW</given-names></name></person-group><article-title>Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>900</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1007/s00125-015-3510-2</pub-id><?supplied-pmid 25677225?><pub-id pub-id-type="pmid">25677225</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santovito</surname><given-names>D</given-names></name><etal/></person-group><article-title>Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control</article-title><source>J Clin Endocrinol Metab</source><year>2014</year><volume>99</volume><fpage>E1681</fpage><lpage>1685</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-3843</pub-id><?supplied-pmid 24937531?><pub-id pub-id-type="pmid">24937531</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunez Lopez</surname><given-names>YO</given-names></name><name><surname>Garufi</surname><given-names>G</given-names></name><name><surname>Seyhan</surname><given-names>AA</given-names></name></person-group><article-title>Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes</article-title><source>Mol Biosyst</source><year>2016</year><volume>13</volume><fpage>106</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1039/C6MB00596A</pub-id><?supplied-pmid 27869909?><pub-id pub-id-type="pmid">27869909</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Delic, D. <italic>et al</italic>. Characterization of Micro-RNA Changes during the Progression of Type 2 Diabetes in Zucker Diabetic Fatty Rats. <italic>Int J Mol Sci</italic><bold>17</bold>, doi:10.3390/ijms17050665 (2016).</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gholamin</surname><given-names>S</given-names></name><etal/></person-group><article-title>The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment</article-title><source>Curr Pharm Des</source><year>2016</year><volume>22</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.2174/1381612822666151112151924</pub-id><?supplied-pmid 26561061?><pub-id pub-id-type="pmid">26561061</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction</article-title><source>J Thorac Dis</source><year>2015</year><volume>7</volume><fpage>303</fpage><lpage>308</lpage><?supplied-pmid 25922707?><pub-id pub-id-type="pmid">25922707</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matkovich</surname><given-names>SJ</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Eschenbacher</surname><given-names>WH</given-names></name><name><surname>Dorn</surname><given-names>LE</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names><suffix>II.</suffix></name></person-group><article-title>Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy</article-title><source>Circ Res</source><year>2012</year><volume>111</volume><fpage>521</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.265736</pub-id><?supplied-pmid 22752967?><pub-id pub-id-type="pmid">22752967</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rooij</surname><given-names>E</given-names></name><etal/></person-group><article-title>A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance</article-title><source>Dev Cell</source><year>2009</year><volume>17</volume><fpage>662</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2009.10.013</pub-id><?supplied-pmid 19922871?><pub-id pub-id-type="pmid">19922871</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>The function of miRNA in cardiac hypertrophy</article-title><source>Cell Mol Life Sci</source><year>2012</year><volume>69</volume><fpage>3561</fpage><lpage>3570</lpage><pub-id pub-id-type="doi">10.1007/s00018-012-1126-y</pub-id><?supplied-pmid 22926414?><pub-id pub-id-type="pmid">22926414</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duong Van Huyen</surname><given-names>JP</given-names></name><etal/></person-group><article-title>MicroRNAs as non-invasive biomarkers of heart transplant rejection</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>3194</fpage><lpage>3202</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu346</pub-id><?supplied-pmid 25176944?><pub-id pub-id-type="pmid">25176944</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy</article-title><source>J Transl Med</source><year>2015</year><volume>13</volume><fpage>314</fpage><pub-id pub-id-type="doi">10.1186/s12967-015-0672-0</pub-id><?supplied-pmid 26404540?><pub-id pub-id-type="pmid">26404540</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaumont</surname><given-names>J</given-names></name><etal/></person-group><article-title>MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>40696</fpage><pub-id pub-id-type="doi">10.1038/srep40696</pub-id><?supplied-pmid 28091585?><pub-id pub-id-type="pmid">28091585</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large AtheroGene study</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><fpage>516</fpage><lpage>523</lpage><?supplied-pmid 27357355?><pub-id pub-id-type="pmid">27357355</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeger</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immunosenescence-associated microRNAs in age and heart failure</article-title><source>Eur J Heart Fail</source><year>2013</year><volume>15</volume><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfs184</pub-id><?supplied-pmid 23258801?><pub-id pub-id-type="pmid">23258801</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Animals, N. R. C. U. C. f. t. U. o. t. G. f. t. C. a. U. o. L. <italic>Guide for the Care and Use of Laboratory Animals</italic>. 8th edn, (National Academies Press (US), 2011).</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>JN</given-names></name><name><surname>Robbins</surname><given-names>J</given-names></name></person-group><article-title>Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse</article-title><source>Am J Physiol</source><year>1997</year><volume>272</volume><fpage>H1137</fpage><lpage>1146</lpage><?supplied-pmid 9087586?><pub-id pub-id-type="pmid">9087586</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Calligaris, S., Ricca, M. &#x00026; Conget, P. Cardiac stress test induced by dobutamine and monitored by cardiac catheterization in mice. <italic>Journal of visualized Experiments</italic><bold>72</bold>, 1&#x02013;6, doi:70.3791/50050 (2013).</mixed-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling</article-title><source>Acta Physiol (Oxf)</source><year>2010</year><volume>200</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20175764</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charan</surname><given-names>J</given-names></name><name><surname>Kantharia</surname><given-names>ND</given-names></name></person-group><article-title>How to calculate sample size in animal studies?</article-title><source>J Pharmacol Pharmacother</source><year>2013</year><volume>4</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.4103/0976-500X.119726</pub-id><?supplied-pmid 24250214?><pub-id pub-id-type="pmid">24250214</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>CL</given-names></name><name><surname>Jensen</surname><given-names>JL</given-names></name><name><surname>Orntoft</surname><given-names>TF</given-names></name></person-group><article-title>Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>5245</fpage><lpage>5250</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0496</pub-id><?supplied-pmid 15289330?><pub-id pub-id-type="pmid">15289330</pub-id></element-citation></ref></ref-list></back></article>